// App-Quantinova.ai

2558 : A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL).

Researchers

Presenter

  • Taofeek Kunle Owonikoko

Principal Investigators

  • Arif Hussain

  • Ana M. Molina

  • Parul Gulati

  • Aadhar Shah

  • Christoph Matthias Ahlers

  • Josephine Cardarelli

  • Lewis J. Cohen

  • Walter Michael Stadler

  • David C. Smith

  • Mario Sznol

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of Maryland Cancer Center, Baltimore, MDYale University, New Haven, CTThe University of Chicago Medicine and Biological Sciences, Chicago, IL

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Bristol-Myers Sqiubb, Princeton, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Thrombocytopenia

  • Neutropenia

  • Solid malignancies

  • Lymphomas

  • Anemia

Biomarkers

  • N/A

Drug/Treatment

  • MDX 1203

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT00944905

Sponsors

  • Bristol-Myer Squibb

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved